Solopharm company in 2016 intends to significantly increase capacity

The project of doubling the capacity of the plant Solopharm in St. Petersburg for the production of liquid sterile drugs came to the finish line. The company invested 2.4 billion rubles, and establishes additional clean room area of 3,500 square meters. m purity classes C and E. Together with 8 new lines it will allow the company to achieve its stated goal: to become the leaders of the hospital segment of sterile liquid pharmaceuticals.
On Solopharm will be installed 2 automatic lines for the production of injectable drugs in the glass for the production of 300 million vials of glass per year. The contract for the supply of these lines was signed in June 2015 and delivery of the lines is scheduled for July 2016. Production line for nasal sprays capacity of 36 million per year will be established in July, 2016.

For this project the company increases capacity of water treatment 3 times and 17 sets of additional reactors, some of them will be the size of 30 thousand. Liters, which will increase the production of each series and reduce the time to stop line.

Minimizing operating costs due to high-quality design of production processes, choice of automatic machinery and equipment, working without participation of the people buying the lines of the latest generation and a reduction in staff costs - all this will allow the company to significantly reduce costs and expenses in the production of medicines.

Company Solopharm increases not only the product of the power and scope. At the moment, about 60 drugs under development and 30 waiting for their registration later this year. Most of them are aimed to replace imported and expensive drugs that come from abroad. About half of these drugs are for sale not only in hospitals and clinics, but the commercial segment in areas such as ophthalmology, ENT medicine and drugs for the treatment of respiratory diseases.